CANADIAN CLINICAL-TRIAL OF ANTILYMPHOCYTE GLOBULIN IN HUMAN CADAVER RENAL-TRANSPLANTATION

  • 1 January 1976
    • journal article
    • research article
    • Vol. 115  (12) , 1205-1208
Abstract
A multicenter, randomized clinical trial of antilymphocyte globulin (ALG) was conducted among patients who underwent cadaver kidney transplantation; follow-up was continued for a minimum of 1 yr. Of the 179 patients, 92 were given conventional treatment only, while 87 were given (in addition) ALG (from a standardized, highly immunosuppressive, common pool of equine ALG), 20 mg/kg (of body wt) for 10 days after transplantation. The ALG-treated group had better accumulated graft survival, fewer nephrectomies, better graft function, less than half the number of acute rejection episodes and less prednisone use. There was a beneficial drug (ALG)-related effect in the graft and the host during the first 3 mo. after transplantation.

This publication has 3 references indexed in Scilit: